![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy
|
|
|
Reported by Jules Levin
AASD 2018 Nov 9-13 SF
![1127181](../images%20/112718/112718-2/1127181.gif)
![1127182](../images%20/112718/112718-2/1127182.gif)
![1127183](../images%20/112718/112718-2/1127183.gif)
![1127184](../images%20/112718/112718-2/1127184.gif)
![1127185](../images%20/112718/112718-2/1127185.gif)
![1127186](../images%20/112718/112718-2/1127186.gif)
![1127187](../images%20/112718/112718-2/1127187.gif)
![1127188](../images%20/112718/112718-2/1127188.gif)
![1127189](../images%20/112718/112718-2/1127189.gif)
![11271810](../images%20/112718/112718-2/11271810.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|